{"id":408352,"date":"2025-09-30T13:30:00","date_gmt":"2025-09-30T11:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=408352"},"modified":"2025-09-11T10:23:15","modified_gmt":"2025-09-11T08:23:15","slug":"editing-genico-intratumorale-mediato-da-nanoparticelle-di-pd-l1-e-galectina-9","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/it\/editing-genico-intratumorale-mediato-da-nanoparticelle-di-pd-l1-e-galectina-9\/","title":{"rendered":"Editing genico intratumorale mediato da nanoparticelle di PD-L1 e galectina-9"},"content":{"rendered":"\n<p><strong>Gli inibitori del checkpoint immunitario (ICI) hanno rivoluzionato la terapia oncologica, ma molti pazienti non rispondono a questa forma di trattamento o lo fanno solo in modo inadeguato. Meccanismi di resistenza come la sovraespressione di PD-L1 o molecole immunosoppressive come la galectina-9 ne limitano l&#8217;efficacia. Un nuovo approccio mira all&#8217;editing genico intratumorale mirato, utilizzando nanoparticelle che introducono i componenti CRISPR-Cas direttamente nelle cellule tumorali e vi spengono i geni regolatori. Un recente studio fornisce la prova preclinica che il silenziamento combinato di PD-L1 e galectina-9 inibisce significativamente la crescita tumorale e migliora l&#8217;efficacia delle terapie ICI.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fediting-genico-intratumorale-mediato-da-nanoparticelle-di-pd-l1-e-galectina-9%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Gli inibitori del checkpoint immunitario (ICI) hanno rivoluzionato la terapia oncologica, ma molti pazienti non rispondono a questa forma di trattamento o lo fanno solo in modo inadeguato. Meccanismi di&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fediting-genico-intratumorale-mediato-da-nanoparticelle-di-pd-l1-e-galectina-9%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":408353,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Nuove prospettive per l'ottimizzazione dell'immunoterapia del cancro","footnotes":""},"category":[11519,11376,11550,11515],"tags":[85218,13611,42052],"powerkit_post_featured":[],"class_list":["post-408352","post","type-post","status-publish","format-standard","has-post-thumbnail","category-formazione-continua","category-oncologia-it","category-rx-it","category-studi","tag-galectina-9","tag-immunoterapia","tag-pd-l1-it","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-16 20:22:30","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"it_IT","wpml_translations":{"pt_PT":{"locale":"pt_PT","id":408398,"slug":"edicao-genetica-intratumoral-de-pd-l1-e-galectina-9-mediada-por-nanoparticulas","post_title":"Edi\u00e7\u00e3o gen\u00e9tica intratumoral de PD-L1 e galectina-9 mediada por nanopart\u00edculas","href":"https:\/\/medizinonline.com\/pt-pt\/edicao-genetica-intratumoral-de-pd-l1-e-galectina-9-mediada-por-nanoparticulas\/"},"es_ES":{"locale":"es_ES","id":408392,"slug":"edicion-genica-intratumoral-mediada-por-nanoparticulas-de-pd-l1-y-galectina-9","post_title":"Edici\u00f3n g\u00e9nica intratumoral mediada por nanopart\u00edculas de PD-L1 y galectina-9","href":"https:\/\/medizinonline.com\/es\/edicion-genica-intratumoral-mediada-por-nanoparticulas-de-pd-l1-y-galectina-9\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/408352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/comments?post=408352"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/408352\/revisions"}],"predecessor-version":[{"id":408354,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/408352\/revisions\/408354"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media\/408353"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media?parent=408352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/category?post=408352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/tags?post=408352"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/powerkit_post_featured?post=408352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}